Skip to main content

Advertisement

SpringerLink
Log in

A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background.Vinorelbine (Navelbin®; N) has proven to be active in patients with advanced breast cancer (ABC) and cyclophosphamide (C) and epirubicin (Epiadriamycin®: E) are still among the main cytostatic agents against this tumor. On this basis was carried out a study to determine the activity and toxicity of the combination of these three agents (CEN).

Patients and method.From April 1996 to March 1998, 59 patients with ABC were recruited of whom 56 were found eligible and evaluable for toxicixty and 55 for activity. The treatment regimen was C: 400 mg/m2, E: 30 mg/m2 and N: 25 mg/m2 administered intravenously on days 1 and 8 of a 28-day cycle.

Results.The median number of cycles administered was 6 (range: 1–16). The most common hematological toxicity was grade (G) 3 and 4 neutropenia occurring in 36% of patients, associated with fever in 7% of them. Grade 3–4 thrombocytopenia and anemia occurred in 5% and 7%, respectively. Other G2–G3 non hematologic toxicities were: N/vomiting in 34%, alopecia in 73% and mucositis in 11% of patients. An objective response was achieved in 28 of 56 patients (50%) (95% confidence interval (CI): 37–63%): complete response (CR) in 9%, partial response (PR) in 41%. The median duration of response, time to progression and overall survival time was 54, 47 and 90 weeks, respectively.

Conclusion.The CEN combination at these doses and treatment schedule appears to have acceptable tolerability but there is no apparent improvement in therapeutic efficacy when compared to other regimens used as first line treatment in ABC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Honing SF: Treatment of metastatic disease. In: Harris JR, Hellman S, Henderson IC, et al (eds) Breast Diseases. Lippincott, Philadelphia, PA, 1996, pp. 669–734

    Google Scholar 

  2. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion doxorubicin in Cooper type regimens. Br J Cancer 67: 801–805, 1993

    PubMed  Google Scholar 

  3. Brambilla C, Rossi A, Bonfante V, et al.: Phase II study of Doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70: 261–266, 1986

    PubMed  Google Scholar 

  4. Hayat M, Chauvergne J, Fargeot P, et al.: Phase III chemotherapy comparing FAC versus FEC in advanced breast cancer: Preliminary results. Proc Am Assoc Clin Oncol C-460, 1984

  5. Intini C, Zingali G, de Micheli P, et al.: FEC versus FAC in Advanced Breast Cancer. Results of an Italian Cooperative study. Cancer Chemother Pharmacol suppl 1 to vol 18: A38, 149, 1986

  6. Potier P: The synthesis of navelbine, prototype of a new series of vinblastine derivates. Semin Oncol 16(4): 2, 1989

    Google Scholar 

  7. Mathe G, Reizenstein P: Phase I pharmacology study of a new vinca-alkaloid: Navelbine. Cancer Lett 27: 285–293, 1985

    PubMed  Google Scholar 

  8. Fumoleau P, Delgado FM, Delozier T, et al.: Phase II trial of weekly intravenous vinorelbine in first line advanced breast cancer chemotherapy. J Clin Oncol 11: 1245–1252, 1993

    Google Scholar 

  9. García Conde J, Lluch A, Martin M, et al.: Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 5: 854–857, 1994

    PubMed  Google Scholar 

  10. Romero A, Rabinovich MG, Vallejo CT, et al.: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12: 336–341, 1994

    PubMed  Google Scholar 

  11. Twelves CJ, Dobbs NA, Curnow A, et al.: A phase II multicentre UK study of vinorelbine in advanced breast cancer. Br J Cancer 70: 990–993, 1994

    PubMed  Google Scholar 

  12. Bruno S, Puerto VL, Mickiewicz E, et al.: Phase II trial of weekly IV vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol 18: 392–396, 1995

    PubMed  Google Scholar 

  13. Weber BL, Vogel C, Jones S, et al.: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13: 2722–2730, 1995

    PubMed  Google Scholar 

  14. Palacio I, De las Peñas R, Esteban E, et al.: Vinorelbina como agente único en el tratamiento del cáncer de mama metastático en segunda línea. Estudio de Fase II del Grupo Oncológico del Noroeste (GON). Neoplasia 13(4): 117–120, 1996

    Google Scholar 

  15. Jones S, Winer E, Vogel C, et al.: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13: 2567–2574, 1995

    PubMed  Google Scholar 

  16. Spielmann M, Dorval T, Turpin F, et al.: Phase II trial of vinorelbine/doxorubicin as first line therapy of advanced breast cancer. J Clin Oncol 12: 1764–1770, 1994

    PubMed  Google Scholar 

  17. Esteban E, Lacave AJ, Fernández JL, et al.: Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. Breast Cancer Res Treat 58: 141–150, 1999

    PubMed  Google Scholar 

  18. Alexander J, Daimak N, Berber HJ, et al.: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300: 278–283, 1979

    PubMed  Google Scholar 

  19. Miller AB, Hoogstraten B, Staquet M, et al.: Reporting results of cancer treatment. Cancer 47: 207–214, 1981

    PubMed  Google Scholar 

  20. Hayward JL, Carbone PP, Heuson JC, et al.: Assessment of response to therapy in advanced breast cancer. Eur J Cancer Clin Oncol 13: 89–94, 1977

    Google Scholar 

  21. Kaplan E, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958

    Google Scholar 

  22. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281, 1984

    PubMed  Google Scholar 

  23. Chadjaa M, Izzo J, May-Levin F, et al.: Preliminary data on 4 épiadriamycin–vinorelbin: a new active combination in advanced breast cancer. Proc. of IV Internat Congress on Anticancer Chemotherapy (SOMPS): 148 (abst P43), 1993

  24. Nistico C, Garufi C, Pace R, et al.: Weekly epirubicin and vinorelbine plus G-CSF in metastatic breast cancer (MBC): high activity with a 75% survival rate at two years Proc Am Soc Clin Oncol: 16: 647, 1997.

    Google Scholar 

  25. Vici P, Amodio A, Di Lauro L, et al.: A multicentric phase II trial of vinorelbine and epirubicin as first line chemotherpary in metastatic breast cancer. Preliminary data. Proc Am Soc Clin Oncol: 18: 437, 1999.

    Google Scholar 

  26. Carmichael J, Hegg R, Firat D, et al.: Navelbine and fractionated dose doxorubicin improves 1st line treatment of advanced breast cancer. An overview of 3 phase II trials. Br J Cancer 75(1): 85: 40, 1997

    PubMed  Google Scholar 

  27. Braud AC, Jauffret E, Thirion P, et al.: Phase II study of vinorelbine, epirubicin and cyclophosphamide (NEC) as first line chemotherapy in patients with metastatic breast cancer: Preliminary results. Proc Am Soc Clin Oncol 18: 433, 1999

    Google Scholar 

  28. Blajman C, Balbiani L, Bloc J, et al.: A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in treatment of advanced breast carcinoma: Cancer 85(5): 1091–1097, 1999

    PubMed  Google Scholar 

  29. Rahman ZU, Frye DK, Smith TL, et al.: Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer 85: 104–111, 1999

    PubMed  Google Scholar 

Download references

Authors
  1. E. Esteban
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. González de Sande
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Puertas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Fra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Palacio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J.M. Vieitez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J.L. Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I. Muñiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Modollel
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. Carrasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M. Sala
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A.J. Lacave
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Esteban, E., Sande, G.d., Puertas, J. et al. A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer. Breast Cancer Res Treat 62, 127–133 (2000). https://doi.org/10.1023/A:1006477109230

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006477109230

Search

Navigation